Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dihexa vs Pinealon
An educational, source-based comparison of Dihexa and Pinealon — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide derived from angiotensin IV that crosses the blood-brain barrier and potentiates hepatocyte growth factor (HGF) / c-Met signaling, associated with new synapse formation in preclinical models.
- Synaptogenesis and dendritic spine density
- Alzheimer's and cognitive aging models
- Memory consolidation in rodents
- • No human clinical trial data; theoretical proliferation concerns via HGF/c-Met.
- • Not FDA-approved.
Short peptide bioregulator researched for cognition and aging.
A synthetic tripeptide (Glu-Asp-Arg) in the Khavinson short-peptide bioregulator family. Research from Russian gerontology groups proposes gene-expression modulation linked to neuronal survival and cognitive performance.
- Cognitive aging in rodent models
- Neuronal apoptosis under oxidative stress
- Circadian and neuroendocrine regulation
- • Most evidence from Russian literature; independent replication is limited.
- • Not FDA-approved.
Dihexa vs Pinealon — Key differences
- Class: Dihexa is classified as Nootropic · Synaptogenesis, while Pinealon is Bioregulator · Neuroprotection.
- Primary research focus: Dihexa — synaptogenesis and dendritic spine density; Pinealon — cognitive aging in rodent models.
- Tag: Cognition vs Cognition · Longevity.